Publication
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (15)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 15
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugLapatinibcivic_curation1.00
- drugNeratinibcivic_curation1.00
- geneERBB2civic_curation1.00
- variantERBB2 D769Hcivic_curation1.00
- variantERBB2 D769Ycivic_curation1.00
- variantERBB2 G309Acivic_curation1.00
- variantERBB2 G778_P780dupcivic_curation1.00
- variantERBB2 L755Scivic_curation1.00
- variantERBB2 L755_T759delcivic_curation1.00
- variantERBB2 L755Wcivic_curation1.00
- variantERBB2 R678Qcivic_curation1.00
- variantERBB2 R896Ccivic_curation1.00
- variantERBB2 V777Lcivic_curation1.00
- variantERBB2 V842Icivic_curation1.00
Curated evidence
Evidence citing this paper (23)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 23220880
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ERBB2 D769H2 | ||||||||
| Lapatinib + NeratinibSubstitutes | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID279In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| (functional) | —UNRESOLVED | Functional | D | Supports Gain Of Function | 3 | submitted | EID10024A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, and L755S) were functionally characterized and tested for sensitivity to lapatinib or neratini… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 D769Y1 | ||||||||
| Neratinib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID280In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 G309A2 | ||||||||
| Neratinib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 5 | accepted | EID282In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| (functional) | —UNRESOLVED | Functional | D | Supports Unaltered Function | 3 | rejected | EID10028A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, and L755S) were functionally characterized and tested for sensitivity to lapatinib or neratini… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 G778_P780dup1 | ||||||||
| Neratinib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID285In MCF10A cell lines, the in-frame insertion of a three amino acids at position (GSP) 780 was shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 L755S3 | ||||||||
| Canertinib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 3 | submitted | EID10022A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, and L755S) were functionally characterized and tested for sensitivity to lapatinib or neratini… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| Lapatinib | Malignant Breast Neoplasm | Predictive | D | Supports Resistance | 5 | accepted | EID241The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| Neratinib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 5 | accepted | EID283The L755S mutation showed mild response to neratinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 L755_T759del3 | ||||||||
| Lapatinib | Malignant Breast Neoplasm | Predictive | D | Supports Resistance | 3 | submitted | EID10021A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, and L755S) were functionally characterized and tested for sensitivity to lapatinib or neratini… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| Neratinib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 2 | accepted | EID281In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| (functional) | —UNRESOLVED | Functional | D | Supports Neomorphic | 3 | submitted | EID10026A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, and L755S) were functionally characterized and tested for sensitivity to lapatinib or neratini… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 L755W1 | ||||||||
| Neratinib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 5 | accepted | EID284MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 R678Q2 | ||||||||
| Lapatinib + NeratinibSubstitutes | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 5 | accepted | EID286MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony forming assay. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| (functional) | —UNRESOLVED | Functional | D | Supports Unaltered Function | 3 | submitted | EID10027A series of HER2 (ERBB2) mutations were functionally characterized and tested for sensitivity to lapatinib or neratinib. Increased tyrosine kinase activity and phosphorylation of signalling proteins w… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 R896C1 | ||||||||
| Neratinib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 5 | accepted | EID287In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 V777L3 | ||||||||
| Neratinib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 5 | accepted | EID288In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| (functional) | —UNRESOLVED | Functional | D | Supports Gain Of Function | 3 | submitted | EID10023A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, and L755S) were functionally characterized and tested for sensitivity to lapatinib or neratini… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| 〃 | —UNRESOLVED | Functional | D | Supports Gain Of Function | 5 | submitted | EID12103The V777L variant is located in the tyrosine kinase domain. In vitro kinase assays were conducted using recombinant expression of the isolated HER2 kinase domain. In this system wild-type (WT) HER2 sh… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 V842I2 | ||||||||
| Neratinib | Malignant Breast Neoplasm | Predictive | D | Supports Sensitivity Response | 5 | accepted | EID289In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib. PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| (functional) | —UNRESOLVED | Functional | D | Supports Gain Of Function | 3 | submitted | EID10025A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, and L755S) were functionally characterized and tested for sensitivity to lapatinib or neratini… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 I767M1 | ||||||||
| (functional) | —UNRESOLVED | Functional | D | Supports Unaltered Function | 3 | submitted | EID10029A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, Y835F, I767M, and L755S) were functionally characterized and tested for sensitivity to lapatin… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |
| ERBB2 Y835F1 | ||||||||
| (functional) | —UNRESOLVED | Functional | D | Supports Unaltered Function | 3 | submitted | EID10030A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, Y835F, I767M, and L755S) were functionally characterized and tested for sensitivity to lapatin… (full text at CIViC) PMID 23220880 · Bose et al., 2013 · Open in CIViC | civic |